Truist raised the firm's price target on Immunome to $37 from $36 and keeps a Buy rating on the shares. The firm is positive on the potential of varegacestat's to penetrate and expand the desmoid tumor market, supported by what it sees as a best-in-class Phase 3 efficacy and safety profile as well as convenient once-daily oral dosing, the analyst tells investors in a research note. Immunome's seasoned ex-Seagen leadership team is also well positioned to replicate prior success through next-wave ADC programs featuring novel Top1i payload/linker technology targeting ROR1 and beyond, the firm added.
